Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Your find validates Leo's decision to back-burner Kevetrin

Kevetrin: Kevetrin (thioureidobutyronitrile) is a small molecule that induces cell cycle arrest and apoptosis in cancer cells through a multi-pronged mechanism that includes the activation and stabilization of p53. Kevetrin inhibited tumor growth and lengthened survival time in ovarian cancer mouse models . A recent phase II clinical trial (NCT03042702) showed stable disease in ovarian cancer patients , but with only two enrolled patients; these results require replication if Kevetrin is to progress as an ovarian cancer treatment.

https://www.mdpi.com/2218-273X/13/1/159

Replication will require tens of millions of dollars that IPIX simply don't have. Further consider that:

In this analysis of US Securities and Exchange Commission filings for 10 cancer drugs, the median cost of developing a single cancer drug was $648.0 million. The median revenue after approval for such a drug was $1658.4 million.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710275/

Further consider:

11. The Future of p53-Based Therapies for HGSOC (High Grade Serious Ovarian Cancer)

The future remains bright for p53-based therapies for the treatment of HGSOC, given the high percentage of p53 mutations. However, there are several obstacles that need to be overcome for this class of therapeutics to be successful. Due to the abundance of heterogeneity associated with HGSOC, it is likely that one single therapy will not suffice for all patients. Therefore, treatment outcomes will depend on a variety of factors including, but not limited to, the following: specific p53 mutation status, BRCA 1/2 status, resistance to chemotherapy agents and/or PARP inhibitors, biomarkers, tumor origin site, stage, and Ad5-neutralizing antibody immunity status. Clinical therapies may need to be tailored based on a comprehensive analysis of these factors. Further research is desperately needed in this field to gain a greater understanding of ovarian cancer, including where it originates, how it spreads, and what biomarkers could be utilized for early detection.

https://www.mdpi.com/2218-273X/13/1/159

IMO, a 2-person trial showing trial showing efficacy is probably not enough to attract suitors interested in ultimately spending hundreds of millions of dollars on K-OC. A potential suitor would also have to consider the 5 other p53 competing therapies (see article) in development as well as the many things we (science) don't fully understand about Ovarian cancer.

I would go as far to say that even if IPIX had the hundreds of millions of dollars to invest, given the many areas of "B" FREE research being conducted by gov'ts and educational institutions, to fully develop K-OC...it wouldn't be a wise investment.

Because many cancers have p53 problems, Kevetrin might have a future in cancer as a combo-therapy and I suspect we won't find out until after K's patent expiration in 2030 for the already stated reasons

Message in reply to:
https://www.mdpi.com/2218-273X/13/1/159
This was published in January 2023. Does the company still own Kevetrin......Leo has never provided us with that answer. I have messaged him on this a few times with no response.

.



.